WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

https://pub.webull.com/us/news-html/2ed113b12bcb49b085ae65c65dce183b.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en BRIEF-Shanghai Hile Bio-Tech, WuXi Biologics To Subscribe to Private Share Placement Of WuXi Vaccines

Summer.76 👍🏼

WuXi Biologics Completed Three Acquisitions to Enhance its Global Network https://finance.yahoo.com/news/wuxi-biologics-completed-three-acquisitions-003000120.html

Thursday picks: WuXi Biologics (02269) target price 130 yuan stop loss price 94 yuan http://www.aimpact.com/article/zho/%E5%91%A8%E5%9B%9B%E7%B2%BE%E9%81%B8-%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9-02269-%E7%9B%AE%E6%A8%99%E5%83%B9130%E5%85%83-%E6%AD%A2%E8%9D%95%E5%83%B994%E5%85%83-3175307363

Bin bei beiden am Start und daher wahrscheinlich falsche Ansprechpartnerin bzgl der 'Entscheidung' 🙃. Wenn du dich informieren magst, schaue gerne die links durch, auch bei der AppTec. Die sind gerade hier doch ziemlich aktuell, bei der WuXi AppTec bin ich da nicht ganz so hinterher.

Hallo zusammen, bin gerade dran mich in das Unternehmen ein zu lesen. WuXi ein zu arbeiten. Was doch sehr komplex ist. Deshalb mal eine Frage zum vereinfachen. Wieso habt ihr euch für die Biologics Aktie entschieden und nicht für das Gesamtpaket WuXiApptec? Danke für eure Antworten.

👍

https://www.wuxibiologics.com/upload/202104/27/ar2020.pdf 2020 Annual Report

👋

Morgen 😎

US  Stocks Jumble; WUXI BIO (02269 HK) Worth Buy-on-dip http://www.aastocks.com/en/stocks/news/aafn-con/.HK.210427_103045/company-news Daiwa Upbeat on WUXI BIO (02269 HK)'s Growth Outlook despite Key Shareholder Unloading http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1094278/company-news

WuXi Biologics reduced its holdings of approximately HK$11.6 billion by major shareholders and its shareholding ratio will drop to 17.44% https://www.reuters.com/article/wuxi-bio-0427-tues-idCNKBS2CE01N

Chinese CDMO sector growing but unlikely to make global impact https://bioprocessintl.com/bioprocess-insider/global-markets/chinese-cdmo-sector-growing-but-unlikely-to-make-global-impact/ China’s contract manufacturing space is growing at over 15% year-on-year but only WuXi Biologics has seen success in attracting global clients, says BioPlan Associates ahead of CPhI Discover. ...

WUXI BIO's Key Shareholder Mulls Placing Shrs at 5.9-8.5% Discount to Raise Up to $10.58B http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1094077/hk-stock-news

Läuft gut aktuell